Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ontruzant

- PMLiVE

Roche’s Vabysmo recommended for EU approval by CHMP for sight loss

If approved, Vabysmo would be the first mechanism of action for nAMD and DME in the EU for over ten years

- PMLiVE

Roche’s diagnostic test for Alzheimer’s receives FDA Breakthrough Device Designation

Alzheimer's affects more than 55 million people globally and is the most common form of dementia

- PMLiVE

Roche announces two-year data confirming Vabysmo improves neovascular age-related macular degeneration

The data showed, after two years, that 60% of patients treated with Vabysmo could be treated every four months, compared with 45% in year one

- PMLiVE

Roche’s Lunsumio granted Priority Review by FDA for people with relapsed or refractory follicular lymphoma

If approved, this could be the first such antibody approved by the FDA for the treatment of any type of non-Hodgkin lymphoma

- PMLiVE

MSD and AstraZeneca announce phase 3 results for prostate cancer therapy

The results show that the Lynparza combination therapy significantly improved radiographic progression-free survival

- PMLiVE

EC approves Roche’s Tecentriq for early-stage lung cancer

Tecentriq has now become the first cancer immunotherapy approved in Europe for the treatment of certain types of early-stage NSCLC

- PMLiVE

Roche’s Polivy receives EC approval for lymphoma therapy

The combination therapy is for patients with previously untreated diffuse large B-cell lymphoma

Roche Basel Switzerland

Roche collaborates with Global Fund to strengthen critical diagnostics infrastructure

The partnership is focused on helping patients with HIV and TB in low- and middle-income countries

Roche Basel Switzerland

Roche reinforces commitment to the World Federation of Hemophilia Humanitarian Aid Program

The company renewed its pledge to provide preventative treatment until 2028 for haemophilia A patients

Roche Basel Switzerland

Roche’s Evrysdi improves survival rates for infants with SMA

The study showed the drug reduced serious adverse events and hospitalisations

Roche Basel Switzerland

Roche shares new positive Ocrevus data for MS patients

The CONSONANCE trial showed treatment with Ocrevus resulted in a majority of patients experiencing no disease progression

- PMLiVE

AstraZeneca and MSD’s breast cancer drug Lynparza receives FDA approval

An estimated 2.3 million patients were diagnosed with breast cancer in 2020

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links